Search

IBM offers a few details of its new consultancy service for R&D management. Pity about the jargon.

USA Today reports declining R&D budgets in the USA, albeit in, it seems, just one tech sector.

Cuts in federal funding have forced UC Berkeley's RAD Lab to seek industry funding. But the money may not be enough to plug the gap.

It may have started from a low base, but the Indian biotech industry is hurtling past the global growth rate. And overseas companies are anxious to get in on the action.

Indian firms are training large numbers of patent agents - with their eye on the large number of companies abroad looking for cheaper patenting.

Universities in Ireland can now bid for funds to beef up their knowledge transfer activities.

Advances in neuroscience are opening up the treatment options for central nervous system diseases - at the same time as the ageing population is increasing the market for these products.

Drug companies finally have an incentive to carry out safety testing in children following new EU legislation approved last week.

The Open Source software movement has broken the stranglehold of expensive, proprietary products. Could the same thing happen in biotechnology?

Scientists from the University of Birmingham, UK, have powered a fuel cell from confectionary waste. They now want to form a consortium with investors and SMEs to apply for an EU Framework grant.

Microsoft Corp. is spinning out some of its software technology to two small European tech ventures, as part of a program to speed development of innovations from its labs.

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

With global revenues of $110 billion last year, and an aging population, the nascent "neurotechnology" market appears poised for huge growth.

The UK government has created two new Enterprise Capital Funds (ECF) under its £40 million scheme to aid high tech businesses caught in the equity gap.

Open source software has broken the stranglehold of proprietary software vendors. Could the Biological Open Source initiative do the same in biotech?

EU technology policy is moving beyond the numbers game, and getting down to economic basics.

The European Commission wants businesses to spend more on research and development - and to help encourage that, the agency is preparing a volley of government proposals for the Autumn.

The lack of funding from the private sector is still holding back the development of the European biotech sector vis a vis the US despite a similar number of companies in each.

Nanomedicine can be more than a case of adding a trendy label to traditional approaches to pharmaceuticals.

Yet another consultation is under way into the safety of nanotechnology. This time you have an opportunity to give your views on "the use of nanotechnologies in relation to food".